Navigation Links
China Biologic Products' High-Purity Human Albumin Research and Development Project to be Listed in the National Torch Plan
Date:2/13/2009

TAIAN CITY, Shandong, China, Feb. 13 /PRNewswire-Asia-FirstCall/ -- China Biologic Products, Inc. (OTC Bulletin Board: CBPO) ("China Biologic" or the "Company"), one of the leading plasma-based pharmaceutical companies in the People's Republic of China ("PRC"), today announced that one of its R&D projects, "High-Purity Human Albumin," will be listed in the National Torch Plan of China.

The National Torch Plan was organized and executed in 1988, by China's Ministry of Science and Technology, to encourage innovation and promote the development of China's high-tech industry. Projects and enterprises listed in the plan have access to a series of support programs provided by the central and local government, including, favorable tax treatment, innovation protection, technical support, and a friendly business environment.

"We are pleased with the acceptance of our project into the National Torch Plan," said Mr. Chao Ming Zhao, CEO of China Biologic. "We view the acceptance of our project as a strong endorsement of our strategy to focus on the research and development of more technologically advanced plasma-based products. We expect that the support from the government provided by the program will enhance our competitive position in the marketplace and help us reach our goal to offer the widest range of plasma-based products in China."

About China Biologic Products, Inc.

Through its indirect majority-owned subsidiary Shandong Taibang Biological Products Co. Ltd. ("Shandong Taibang"), China Biologic Products, Inc., a Delaware corporation (the "Company"), is principally engaged in the research, development, production and manufacturing and sale of plasma-based biopharmaceutical products to hospitals and other health care facilities in China. The Company's human albumin products are mainly used to increase blood volume and its immunoglobulin products are used for the treatment and prevention of diseases.

Safe Harbor Statement

This release may contain certain "forward-looking statements" relating to the business of China Biologic Products, Inc. and its subsidiary companies. All statements, other than statements of historical fact included herein are "forward-looking statements," including statements regarding: the significance of the selection of the Company's High-Purity Human Albumin R&D project for listing in China's National Torch Plan and its effect on the Company's ability to increase its overall production capacity, revenues and market share; the ability of the Company to achieve its commercial objectives, including its goal to offer the widest range of plasma-based products in China; the business strategy, plans and objectives of the Company and its subsidiaries; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website ( http://www.sec.gov ). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

    For more information, please contact:

    Company Contact:
     Mr. Y. Tristan Kuo
     CFO
     China Biologic Products, Inc.
     Tel:   +86-538-6202206
     Email: IR@chinabiologic.com
     Web:  http://www.chinabiologic.com

    Investor Relations Contact:
     Mr. Crocker Coulson, President
     CCG Investor Relations
     Tel:   +1-646-213-1915 (NY office) or
     Mr. Gary Chin
     Tel:   +1-646-213-1909
     Email: crocker.coulson@ccgir.com
     Web:  http://www.ccgirasia.com

'/>"/>
SOURCE China Biologic Products, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
4. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
5. China Technology Announces New Chief Financial Officer
6. China Medical Technologies Reports First Quarter Financial Results
7. China Medical Technologies to Participate in Credit Suisses 2007 Asian Technology Conference
8. China Technology Announces Entry to the Solar Energy Sector
9. China Sky One Medical Receives $1.5 Million Government Grant to Further Develop Six New Cancer Products
10. Kiwa Bio-Tech Named Recommended Brand by the China Green Food Association
11. China Kangtai Cactus Biotech, Inc. Announces Plans for New Product Launch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... VA (PRWEB) , ... March 29, 2017 , ... ... wearable patch comprising multiple separable adhesive layers, as issued by the U.S. Patent ... layers as it applies to combining electronics and health monitoring. This invention will ...
(Date:3/29/2017)... "Surging application of gesture control features in ... expected to drive the growth of gesture recognition and ... is expected to be worth USD 18.98 billion by ... and 2022. The touchless sensing market is expected to ... a CAGR of 17.44% between 2017 and 2022. Gesture ...
(Date:3/29/2017)... Alto, CA, USA (PRWEB) , ... March 29, 2017 , ... ... in various regulatory subjects has announced its 3rd Annual Medical Device Summit 2017 venue ... at the Omni Parker House Hotel, in Boston, MA. , The Omni Parker House ...
(Date:3/29/2017)... Washington, DC (PRWEB) , ... March 29, 2017 ... ... Inc. announced today that it is exhibiting in booth 513 at the Association ... Renaissance Washington, DC Downtown Hotel, March 29-31. , CANCERSCAPE unites key stakeholders ...
Breaking Biology Technology:
(Date:3/22/2017)... -- Vigilant Solutions , a vehicle location and ... today the appointment of retired FBI special agent ... development. Mr. Sheridan brings more than 21 ... on the aviation transportation sector, to his new role ... served as the Aviation Liaison Agent Coordinator (ALAC) in ...
(Date:3/13/2017)... March 13, 2017 Future of security: Biometric Face Matching ... ... DERMALOGs Face Matching enables to match face pictures against each ... to identify individuals. (PRNewsFoto/Dermalog Identification Systems) ... DERMALOG,s "Face Matching" is the fastest software for biometric Face Matching on ...
(Date:3/7/2017)... , March 7, 2017   HireVue , ... top global companies identify the best talent, faster, today ... Chief Sales Officer (CSO) and Diana Kucer ... round out a seasoned executive team poised to drive continued ... building on a year of record bookings in 2017. ...
Breaking Biology News(10 mins):